WT1 Peptid Vaccination in Carcinomas

Charité University Medicine Berlin

Status and phase: Unknown; Phase 2

Conditions: WT1 Expressing Carcinoma

Treatments: Biological: WT1 126-134 peptide

Study type: Interventional

Funder types: Other

Identifiers

NCT00153608

HaemaCBFWT104

EU

Details and patient eligibility

About

In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic cancer, no standard treatment option
• Resected cancer with minimal residual disease, no standard treatment option
• WT-1 expression
• HLA-A2

Exclusion criteria

• Concurrent chemotherapy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)